Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Finranks

Kompaniya

  • Biz haqimizda

Biz bilan bog'lanish

  • [email protected]

Bizni kuzating

  • Instagram
  • Telegram
  • LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari
  • Bosh sahifa
  • Bozorlar
  • Skriner
  • Yangiliklar
  • Biz haqimizda
  1. Home
  2. ANIK
A

Anika Therapeutics, Inc. (ANIK)

14.28

0.00 (0.00%)

  • Umumiy
  • Yangiliklar
  • Grafik
  • Hisobotlar
  • Dividendlar
  • Kutilma
  • Egalik
  • Profil
Top 2 Health Care Stocks That May Crash This Quarter
04.03.2026

Top 2 Health Care Stocks That May Crash This Quarter

As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
26.02.2026

Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
26.02.2026

Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates

Anika Therapeutics (ANIK) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.03 per share a year ago.

Anika Reports Fourth Quarter and Full Year 2025 Financial Results
26.02.2026

Anika Reports Fourth Quarter and Full Year 2025 Financial Results

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2025.

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
18.02.2026

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference

BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event.

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
12.02.2026

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
26.01.2026

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options

Videolar

No Data

There is no data to display